Results 121 to 130 of about 9,451 (197)

Patient outcomes in KCNQ2 developmental and epileptic encephalopathy

open access: yesDevelopmental Medicine &Child Neurology, Volume 68, Issue 8, Page 1063-1071, August 2026.
Abstract The aim of this study was to review and summarize the literature describing clinically observed or caregiver‐reported and patient‐reported KCNQ2 developmental and epileptic encephalopathy (DEE) outcomes. Three online databases and selected congress proceedings were searched (August 2023).
Grant Maclaine   +9 more
wiley   +1 more source

Biomarker‐Based Diagnosis and Care Pathways for Alzheimer's Disease in the Era of Disease‐Modifying Treatments: A Consensus Statement by Belgian Experts

open access: yesEuropean Journal of Neurology, Volume 33, Issue 8, August 2026.
ABSTRACT Background The recent approval of disease‐modifying therapies (DMTs) for early Alzheimer's disease (AD) marks a major shift in clinical practice. Biomarker confirmation of amyloid pathology is now required alongside clinical assessment, and blood‐based tests are improving accessibility.
Tim Van Langenhove   +31 more
wiley   +1 more source

ATP1A3-related syndromes: our case-series unveiling a dynamic, fever-triggered and overlapping array of neurological phenotypes. [PDF]

open access: yesNeurol Sci
Errichiello G   +10 more
europepmc   +1 more source

Rhesus macaques with an <i>OPA1</i> mutation demonstrate features of autosomal dominant optic atrophy. [PDF]

open access: yesProc Natl Acad Sci U S A
Jaggers TN   +27 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy